Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 2Colonic Neoplasms 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 51Carboplatin 21Paclitaxel 20Cyclophosphamide 18Nivolumab 13Taxes 10130-nm albumin-bound paclitaxel 10olaparib 9Specimen Handling 9spartalizumab 8fludarabine 8Doxorubicin 8durvalumab 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Cisplatin 7Biopsy 7veliparib 6atezolizumab 6Fulvestrant 6Albumin-Bound Paclitaxel 6liposomal doxorubicin 5eribulin 5budigalimab 5Irinotecan 5Ipilimumab 5aldesleukin 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Triple Negative Breast Neoplasms × HMPL-013 × Clear all
NCT03251378 2024-09-25

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Hutchmed

Phase 1 Completed
129 enrolled 32 charts
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡